Position in LLY
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$9,967,264
-$20,368,590 QoQ
Shares Held
8,310
-74.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.21%
of 13F equity value
Holder Rank
#1,256
of 4,605 holders
Holding Since
Mar 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Y-Intercept (Hong Kong) Ltd holds $55,696,959 across 11 Drug Manufacturers - General names. LLY ranks #2 (17.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
74,248 | $18,683,766 | |
| 2 | LLY |
ELI LILLY & Co
This page
|
8,310 | $9,967,264 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
57,007 | $7,202,264 | |
| 4 | MRK |
Merck & Co., Inc.
|
51,433 | $6,609,140 | |
| 5 | NVO |
Novo Nordisk A S
|
86,018 | $4,123,702 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
46,615 | $2,685,956 | |
| 7 | AMGN |
Amgen Inc
|
5,281 | $1,912,355 | |
| 8 | GSK |
GSK plc
|
24,289 | $1,273,229 |
All Filings in LLY
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,967,264 | 8,310 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $30,335,854 | 32,982 | Shares | Sole | 2026-04-27 | |
| 2025-03-31 | $1,895,463 | 2,295 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $4,137,920 | 5,360 | Shares | Sole | 2025-02-04 | |
| 2024-09-30 | $14,078,472 | 15,891 | Shares | Sole | 2024-11-15 | |
| 2023-12-31 | $1,339,550 | 2,298 | Shares | Sole | 2024-02-13 | |
| 2022-03-31 | $605,672 | 2,115 | Shares | Sole | 2022-05-16 | |
| 2021-09-30 | $874,755 | 3,786 | Shares | Sole | 2021-11-15 | |
| 2021-03-31 | $2,030,546 | 10,869 | Shares | Sole | 2021-05-12 | |
| No filing history on record for this holder in this stock. | ||||||